NOD2 Agonist Small Molecules for Vaccine Adjuvant Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants primarily rely on canonical nucleic acid agonists for TLRs, with a need to explore NOD2-active compounds as agonists for TLRs and NLRs, and identify novel, non-canonical immunostimulatory small molecules for innate immune receptors.
Innovation Solution
Development of compounds with NOD2-agonistic activity, specifically 1-substituted-1H-benzo[d]imidazole derivatives that stimulate the immune system by activating NOD2 or TLR7/8 receptors, used as vaccine adjuvants to regulate cytokine and chemokine secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If canonical nucleic acid agonists are used for TLRs, then TLR activation is achieved, but the ability to activate NOD2 and explore novel immunostimulatory mechanisms is limited
Solution Approach 1:
The patent applies parameter changes by modifying molecular structure parameters - transitioning from canonical nucleic acid structures to small molecule structures with specific chemical features (imidazole core, substituted aromatic rings). This structural parameter change enables activation of both TLRs and NOD2, expanding receptor activation capability while maintaining manageable molecular complexity
Solution Approach 2:
The patent achieves universality by designing compounds that can activate multiple innate immune receptors including TLRs and NOD2. The small molecule compounds possess multiple functional groups and structural features that enable them to interact with different receptor types, making a single compound capable of stimulating diverse immune pathways
2Adaptability or versatility
If small molecule agonists are developed for NOD2, then novel immunostimulatory activity is achieved, but specificity and selectivity may be compromised
Solution Approach 1:
The patent applies local quality by incorporating specific functional groups and structural motifs at particular positions within the molecule. The imidazole core with specific substituents creates localized interaction zones that confer selectivity for NOD2 while maintaining overall immunostimulatory activity. Different regions of the molecule are optimized for specific receptor interactions
Solution Approach 2:
The patent employs dynamics by designing molecules with flexible substituents and rotatable bonds that allow the compound to adapt its conformation during receptor binding. This dynamic flexibility enables the small molecule to achieve high affinity and specificity for target receptors while maintaining the ability to interact with multiple receptor types
3Productivity
If compounds are designed to activate multiple TLRs and NOD2, then broad immune stimulation is achieved, but off-target effects and lack of selectivity may increase
Solution Approach 1:
The patent applies partial action by designing compounds that provide baseline activation of multiple receptors at low levels, with the ability to be selectively enhanced for specific receptor pathways. This allows broad immune stimulation at sub-maximal levels while avoiding excessive activation that could lead to off-target effects and inflammation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively induce cytokines and chemokines, enhancing immune activity and adjuvantic effects, particularly for TLR7 and TLR8 stimuli, while maintaining specificity and avoiding activity in human blood-based assays.
Implementation Method 1
compounds with NOD2-agonistic activity that are useful as vaccine adjuvant potentiators... stimulating the immune system by activating NOD2 or TLR7/8 receptors
Data Source
AI summary
The invention provides a compound of formula I:or a salt thereof, wherein R1, R2, R3, A and n have any of the values described in the specification, as well as compositions comprising a compound of formula I, and methods of preparing and use thereof. The compounds are useful as vaccine adjuvant potentiators.